Company News-宜明昂科英文

2025-07-02

IMM2510/AXN-2510 receives FDA IND clearance for phase 1b/2 trial

SHANGHAI and DALLAS,TX, July 2, 2025 (GLOBE NEWSWIRE)– ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, “ImmuneOnco”) and Instil Bio, Inc. (Nasdaq: TIL, "Instil") , today announced the clearance of an Investigational New Drug (IND) application for IMM2510/AXN-2510 by the U.S. Food and Drug Administration.

2025-06-25

Immuneonco's IMM0306 Phase Ib Clinical Trial for Systemic Lupus Erythematosus (SLE) Achieves Positive Results with Remarkable Efficacy and Excellent Safety

IMM0306 has demonstrated a strong efficacy signal in the preliminary data for SLE, with efficient and sustained B-cell depletion and immune reconstitution. It has shown rapid and dose-dependent improv

2025-05-22

ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated in 2H 2025

ImmuneOnco Announce Clinical Update for the IMM2510/AXN-2510

2025-05-15

The National Medical Products Administration (NMPA) Approved ImmuneOnco’s Clinical Trial Application for Tazlestobart (IMM27M) Combined with Osimertinib in Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Squamous Non-Sma

On May 15, 2025, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (referred to as “ImmuneOnco,” Hong Kong Stock Exchange stock code: 01541.HK) announced that the Phase Ib/II clinical trial application fo

2025-05-07

Further Payment Received Under the License and Collaboration Agreement with Axion Bio for IMM2510 (Palverafusp α) and IMM27M (Tazlestobart)

This announcement is made by ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (the “Company,” together with its subsidiaries, the “Group”) on a voluntary basis to inform shareholders and potential inve